PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1477115
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1477115
Xenotransplantation Market size was valued at USD 13,305.1 Million in 2023, expanding at a CAGR of 10.2% from 2024 to 2032.
Xenotransplantation is the process of transplanting living cells, tissues, or organs from one species to another. It typically refers to transplanting organs or tissues from animals into humans. The rising incidence of organ failure due to factors like aging populations, lifestyle diseases, and chronic conditions increases the demand for alternative transplant options. However, the risk of immune rejection and transmission of infectious diseases from the donor animal to the recipient poses significant challenges to the widespread adoption of xenotransplantation. Moreover, advances in gene editing technologies like CRISPR/Cas9 offer opportunities to address immunological barriers and potentially expanding the pool of transplantable organs.
Xenotransplantation Market- Market Dynamics
Increasing need for tissue and organ transplantation
Xenotransplantation could potentially provide an alternative source of organs and tissues for transplantation, thereby expanding the supply beyond what is available from human donors. This is particularly important given the shortage of human organs and tissues for transplantation, leading to long waiting lists and high mortality rates for patients in need. The development of xenotransplantation technologies requires significant research and innovation, which can also lead to advancements in other areas of medicine. World Health Organization (WHO) have set regulations for clinical trials of a donor as xenotransplantation carries the potential risk of the transmission of infection with the cells or tissues of the graft. The degree of risk is unknown in the absence of clinical trials.
Xenotransplantation Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.2% over the forecast period (2024-2032)
Based on application segmentation, organ transplantation was predicted to show maximum market share in the year 2023
Based on end users segmentation, hospitals & clinics was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Xenotransplantation Market is segmented on the basis of Product, Application, End User, and Region.
The market is divided into five categories based on application: Xenotransplantation, the process of transplanting organs or tissues from one species to another, has the potential to address the critical shortage of human organs for transplantation. Xenotransplantation could provide an alternative source of organs, reducing the dependency on human donors, which are often in short supply.
The market is categorized into three categories based on end user: : Xenotransplantation could address the shortage of human organs for transplantation by using organs from animals, such as pigs, which have anatomical and physiological similarities to humans. This could potentially save the lives of patients awaiting organ transplants. Xenotransplantation can be used in tissue engineering to create biological scaffolds or matrices for tissue regeneration and repair.
Xenotransplantation Market- Geographical Insights
North America's strong progress in the medical field and the growing number of organ failure cases contribute to the region's leadership in the xenotransplantation market. The region is equipped to take the lead in the development and application of cutting-edge medical technologies like xenotransplantation because of its existing infrastructure, research skills, and healthcare investments. Additionally, the growing population in the Asia-Pacific region raises the need for healthcare services, particularly xenotransplantation.
Xenotransplantation market involves various players including biotechnology companies, pharmaceutical companies, academic institutions, and research organizations. Several of the leading companies in the "Global Xenotransplantation Market" are included in it, including Preservation Solutions, OrganOX Limited, B. Braun Medical Institute, Terumo Medical Corporation, Roche, Astellas Pharma, and Sino-Clone Organ Biotechnology. For instance, eGenesis is a biotechnology company focused on using gene editing technologies to develop xenotransplantation solutions. They are known for their work in genetically modifying pigs to make their organs more compatible with humans. These companies are actively involved in research, development, and commercialization efforts to advance xenotransplantation technologies and bring them to market. For instance, in March 2024, world's first genetically-edited pig kidney transplant into living recipient performed at massachusetts general hospital.
In March 2023, Johns Hopkins Medicine received $21.4 million to advance viability of animal organs for transplants and enable human clinical trials.
GLOBAL XENOTRANSPLANTATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Terumo Medical Corporation
Transonic
F. Hoffmann-La Roche Ltd.
Astellas Pharma, Inc.
Preservation Solutions, Inc.
OrganOX Limited
Bio Med Pvt. Ltd.
Transplant Biomedical
TransMedic, Pte. Ltd.
Novartis AG
Organ Recovery Systems
Accord Healthcare
Pfizer, Inc
Veloxis Pharmaceuticals, Inc.
Others